| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers B > Headlines for Boehringer Ingelheim > News item |
Galapagos' BioFocus division to collaborate with Boehringer Ingelheim on autoimmune diseases
By E. Janene Geiss
Philadelphia, Jan. 17 - BioFocus, the service division of Galapagos, said that it has signed a new three-year collaboration agreement with Boehringer Ingelheim in the field of autoimmune discovery research.
Under the terms of the agreement, BioFocus will expand its SilenceSelect si-RNA based gene collection with an additional gene set, develop a dedicated cellular assay in the field of autoimmune disease and use this assay to run a target discovery screen, according to a company news release.
As part of the collaboration, Galapagos said it will receive upfront fees and research and development funding. The company said it may receive milestone fees when certain drug discovery criteria are met.
Should all targeted criteria be achieved, total potential contract value for Galapagos may exceed €2 million, officials said.
"This collaboration capitalizes on Galapagos' know-how in the autoimmune field and the strength of its target discovery platform. We are delighted to be Boehringer Ingelheim's partner in this disease discovery program," Onno van de Stolpe, chief executive officer of Galapagos, said in the release.
Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. There currently are more than 40 known human diseases classified as either definite or probable autoimmune diseases, affecting 5% to 7% of the population, officials said.
Galapagos is a Mechelen, Belgium, genomics-based drug discovery company that uses its proprietary, novel targets to development therapeutics for bone and joint diseases, osteoarthritis, osteoporosis and rheumatoid arthritis.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.